Emuliquen simple

Quick links to important sections

Emuliquen simple

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emuliquen simple

Property Description
Active ingredient Liquid Paraffin
Form Oral Emulsion
Pharmacological class Lubricant Laxative
General Purpose Facilitating the passage of intestinal contents
Origin/Type Mineral/Hydrocarbon

What is Emuliquen simple and What is its Pharmacological Class?

Emuliquen simple is a specialized pharmaceutical preparation formulated as an oral emulsion for oral administration, primarily intended to facilitate intestinal transit and elimination. This medicine is classified within the Lubricant Laxative group. This designation confirms the general function of the preparation is to physically ease elimination, a mechanism long recognized within pharmacological studies.

The product’s structure as an oral emulsion is a differentiating factor, providing a homogenized, liquid medium for delivery. Unlike osmotic agents, this preparation's action is focused on the physical modification of the intestinal contents, a principle supported by established medical consensus regarding mineral oil as a stool lubricant.

Key Components: Liquid Paraffin and Excipients

The core identity of Emuliquen simple is centered on its composition, which features Liquid Paraffin as the sole active ingredient in this specific formulation. Liquid Paraffin is a highly stable, non-absorbable Mineral/Hydrocarbon lubricant.

As a Lubricant Laxative, Liquid Paraffin performs its function locally within the gastrointestinal tract, working by a physical mechanism. This method is distinct from stimulant laxatives and is clinically recognized for its ability to soften the stool and reduce friction. The preparation’s origin and nature are defined by this inert, non-absorbable oil, which is presented in an aqueous liquid emulsion base.

What is the General Purpose of this Preparation?

The general purpose of the Emuliquen simple preparation is to support regular and comfortable bowel function by modifying the physical characteristics of the intestinal contents. It achieves its function as a laxative by providing effective intestinal lubrication, which is a typical use scenario when hard, dry stool is the primary concern.

The preparation’s fundamental physiological action is to physically soften and coat the stool, thereby facilitating easier transit and minimizing the effort required during defecation. This focus on stool softening makes the product generally useful for alleviating the symptoms associated with occasional or difficult elimination.

Regulatory References

  1. Mineral Oil Laxative (NIH DailyMed)

What side effects are possible with Emuliquen simple?

Possible Side Effects and Safety Information

The official safety profile for products containing Liquid Paraffin (Mineral Oil), such as Emuliquen simple, is defined by its physical action as a lubricant laxative, according to government regulatory documents. Adverse reactions are formally classified by frequency and associated System-Organ Class (SOC).

Adverse Reaction Classification

The most commonly observed effects are classified under Gastrointestinal Disorders. These include anal seepage (leakage of the oil), which is listed as a common reaction, and less frequent issues such as pruritus ani and perianal irritation, which are categorized as uncommon.

Serious Adverse Reactions and Safety Constraints

The official regulatory text highlights the risk of lipoid pneumonia as a rare but serious adverse reaction. This condition occurs if the oil is accidentally inhaled (aspirated) into the lungs, and it is the primary factor driving specific safety constraints. Consequently, the product is associated with heightened risks in specific populations, including older adults and children, particularly those with known swallowing difficulties or conditions that increase the risk of aspiration.

Furthermore, official documentation defines safety notes regarding exposure duration. The long-term exposure or chronic use of Liquid Paraffin is associated with the potential for reduced absorption of fat-soluble vitamins (A, D, E, K). The product may also interfere with the absorption of certain other orally administered medicines. These regulatory statements structure the product's safety profile around local physical effects, the critical aspiration risk, and systemic consequences of chronic use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the active ingredient, Liquid Paraffin, is documented by regulatory authorities to result from excessive oral ingestion or inappropriate prolonged use. Symptoms of acute overdosage are centered on severe gastrointestinal hyper-laxation, manifesting as excessive purgation and watery diarrhoea. Extended overuse is officially associated with the complication of impaired absorption of fat-soluble vitamins (A, D, E, and K).


Documented Severe Outcomes and Risks

  • The most severe risk documented is lipoid pneumonia, a life-threatening complication that may occur following the accidental inhalation or aspiration of liquid paraffin.
  • Regulatory warnings explicitly note that Older Adults or bedridden patients are at an increased risk of aspiration and subsequent pulmonary complications.
  • Excessive dosage or prolonged use may also result in anal seepage and associated anal irritation.

When Immediate Medical Help is Required

Official regulatory guidance mandates specific actions in the event of an overdose or suspected aspiration:

  • Seek immediate medical help or contact a Poison Control Center right away.
  • This action is required if overdose is suspected or if the medicine is suspected of being accidentally inhaled.

Management is primarily symptomatic and supportive, aiming to address the effects of hyper-laxation, and requires immediate discontinuation of treatment. No specific antidote for Liquid Paraffin overdose is listed in official prescribing information.

Therapeutic Uses of Emuliquen simple

What Emuliquen Simple Treats: Main Uses and Benefits

The medication is applied in situations involving certain symptoms related to physical discomfort and temporary functional strain. The active ingredient is relevant for the temporary relief of constipation, supporting symptom management during episodes of heightened discomfort. It is commonly used across conditions presenting with episodic or fluctuating manifestations that produce symptomatic burden, offering assistance in easing symptoms related to occasional digestive issues.


Therapeutic Applications and Symptom Support

Emuliquen Simple is primarily used in areas where short-term symptomatic support is appropriate for symptoms that interfere with daily functioning and create noticeable functional strain. The medication is relevant in contexts marked by increased discomfort or tension, assisting with maintaining functional stability when symptoms become more noticeable. This medicine is considered relevant when symptoms of occasional constipation require supportive relief to assist with easing the overall symptom load.

“It provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic phases.”

Supportive Focus

Supportive Focus: Addressing Episodic Discomfort

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

The eligibility profile for Emuliquen simple (Liquid Paraffin oral emulsion) is strictly defined by regulatory documents, outlining populations that are permitted to use the medicine and those who are expressly contraindicated.

Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with established conditions that compromise gastrointestinal integrity, including intestinal obstruction, gastrointestinal perforation, or inflammatory bowel diseases. It is also prohibited in cases of undiagnosed abdominal pain, appendicitis symptoms, or severe intestinal spasms. Patients with difficulty swallowing (dysphagia) must not use this product due to the serious risk of aspiration.

Age-Based Restrictions

The medicine is contraindicated in children under 6 years of age. Use is generally reserved for adults and adolescents over 12 years. Children between 6 and 12 years are eligible, but use requires caution and is subject to special regulatory consideration.

Conditional and Restricted Use

Certain vulnerable populations, such as the elderly, bedridden, or disabled patients, must consult a doctor prior to use due to the heightened risk of aspiration. Furthermore, the medicine is intended for occasional use only; prolonged administration is not recommended due to the risk of tolerance or dependence. During pregnancy, use is not recommended unless the expected benefit is greater than potential risks; use during lactation must be medically evaluated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

[Emuliquen simple] (Liquid Paraffin) is a lubricant laxative whose interaction profile is defined by its physical action of coating the intestinal wall. This mechanism can lead to a pharmacokinetic interaction characterized by absorption impairment of co-administered substances, a pattern documented in regulatory labeling.


Administration-Timing Restrictions

Official labeling mandates specific administration-timing rules to prevent physical interference with the systemic uptake of other substances:

  • Other Oral Medicines: It is required that the product be administered with a time separation, specifically taken 2 or more hours before or after other drugs.
  • Food: The product must not be taken with meals to avoid interfering with the absorption of essential nutrients.

Substances Affected by Absorption Impairment

The physical presence of Liquid Paraffin may reduce the proper systemic absorption and, consequently, the effectiveness of certain orally administered substances. This is defined as a clinically significant interaction requiring caution.

Affected Substance Category Interaction Outcome Regulatory Basis
Fat-soluble Vitamins (A, D, E, K) Decreased absorption and reduced systemic exposure. Official Labeling
Anticoagulants (e.g., Warfarin) Interference with absorption, potentially affecting blood levels. Official Labeling
Digitalis Glycosides Interference with proper absorption and reduced effectiveness. Official Labeling
Oral Contraceptives Interference with proper absorption and reduced effectiveness. Official Labeling

No formal contraindicated drug-drug combinations or metabolic enzyme (CYP-mediated) interactions are documented for this product.

Mechanism of Action

How Emuliquen Simple Works

Emuliquen Simple operates exclusively through physical mechanisms confined to the gastrointestinal lumen; it does not engage molecular targets such as receptors or enzymes. The active component, liquid paraffin, targets the fecal mass and the surface of the intestinal mucosa.

Fecal Mass Softening and Hydration

Within the colon, the non-digestible liquid paraffin permeates the solid fecal mass, resulting in altered consistency. Concurrently, it creates a hydrophobic coating, acting as a physical barrier that restricts the reabsorption of water by the colon's epithelial lining. This process maintains the stool's water content and volume, directly producing a softer, more pliable consistency.

Lower GI Tract Lubrication

Separately, the oil coats the inner surface of the colon wall. This physical lubrication action reduces the mechanical resistance between the fecal mass and the intestinal tissues. By lowering this drag, the mechanism supports the efficiency of intestinal peristalsis to move the material. The outcome of these combined physical actions is the facilitated transit of material through the lower digestive tract.

Dosage and Administration Information

How to Use Emuliquen simple

The administration of Emuliquen simple (a Liquid Paraffin oral emulsion) is governed by established instructions defining the appropriate route, dosage, and duration of use.

Dosage Regimens and Frequency

Age Group Standard Dose Volume Maximum Daily Volume
Adults (ge 12 years) 15 mL 30 mL
Children (6 to 12 years) 5 mL 10 mL

Administration is strictly limited to the oral route. The primary dose is taken once daily, preferably in the evening before bedtime. If a second administration is required, it must be taken in the morning. The medicine is not approved for administration to children under six years of age.

Administration Conditions and Duration

The timing of the administration is subject to a mandatory constraint: the dose must be separated from any meal by a minimum of two hours, both before and after ingestion. This separation is specified to prevent potential issues with absorption.

The preparation must be shaken well and diluted in a beverage such as water, milk, or juice prior to consumption. A procedural requirement states that the medicine must not be taken while lying down.

The preparation is intended only for short-term use, with treatment courses generally not exceeding seven consecutive days. Consistent with official use patterns, the dosage should be progressively reduced as the desired effect is achieved, and treatment should be discontinued when possible.

Recent Clinical Evidence

Research evidence / Overview of studies for Emuliquen simple

Evidence for use in Constipation (Functional and Chronic)

Research has examined the use of Liquid Paraffin, the active ingredient in Emuliquen simple, primarily in the context of conditions characterized by fluctuating or episodic manifestations such as chronic functional constipation. Studies in this area utilize Randomized Controlled Trials (RCTs) to compare the medicine against no treatment or against other agents studied for constipation. Researchers designed these studies to monitor key outcomes describing episodic or acute changes, including changes in weekly bowel movement frequency and patient-reported outcomes describing perceived discomfort like straining and painful defecation.

Trials monitored how symptoms were reported in the study populations over defined, short time intervals. Studies reported measurements of changes in stool frequency and discomfort levels related to Liquid Paraffin. In some comparative studies, research described patterns where the rate of painful defecation was observed in some studies to be lower in specific study groups receiving this agent compared to groups receiving certain alternative agents, such as lactulose. However, the evidence is limited by certain research structures.

Comparative Evidence Landscape

Much of the available evidence for Liquid Paraffin was evaluated in settings that compare it directly with other treatments, rather than against an inactive substance (placebo). This research primarily focused on the relative outcomes tracked during the study period. Comparative trials have explored outcomes against both lactulose and polyethylene glycol (PEG).

Research describes patterns where stool frequency was measured comparably in some studies evaluating Liquid Paraffin against PEG over short-term periods. The evidence quality varies across studies, particularly in systematic reviews that summarize findings from multiple small trials. This variability contributes to understanding symptom patterns but means that certainty remains low regarding the comparative standing of Liquid Paraffin against newer agents.

What is Still Uncertain About the Research Evidence

A primary finding from systematic reviews is that evidence is limited by structural gaps in the research base. Sample sizes were modest in many of the older trials. There is limited information for long-term outcomes regarding the sustained characteristics of the research subject. The short duration of many trials means that the effect on sustained outcomes reflecting daily functioning or activity level over many months is not fully established. Research provides context but not individual predictions because study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. HPRA Summary of Product Characteristics for Emuliquen simple

Frequently Asked Questions (FAQ)

Common questions about Emuliquen simple (FAQ)


Q: Is Emuliquen simple the same as other laxatives?

Regulatory documents classify Emuliquen simple as a lubricant laxative and a stool softener. This means it works by a specific physical mechanism—softening the stool and lubricating the intestinal lining—which is distinct from the way other laxative classes, like bulk-forming or osmotic agents, operate.


Q: How quickly can someone expect to feel the effect of Emuliquen simple?

Administration guidance is structured to support achieving the effect (defecation) by the following morning after a night-time dose. According to regulatory texts, the full laxative effect is typically described as being achieved from the third day after starting the treatment course.


Q: Does Emuliquen simple cause dependency if used for a long time?

Official information indicates that the prolonged use of this medicine is not recommended. This caution is in place because extended administration may lead to tolerance (meaning the dose works less effectively) and dependence on the laxative effect to achieve bowel movements.


Q: Does Emuliquen simple affect the absorption of vitamins or other nutrients?

Regulatory documents describe the potential for the product to interfere with the absorption of fat-soluble vitamins (A, D, E, K, etc.). It may also interfere with the absorption of certain minerals like calcium and phosphorus due to its physical presence in the digestive tract.


Q: What is the consistency or taste of Emuliquen simple?

Regulatory documents describe the product as an oral emulsion and note that a slight separation of the aqueous phase may be observed. The product is required to be diluted in a beverage prior to consumption.


Q: Does Emuliquen simple need to be taken at a specific time of day?

Official administration guidance suggests taking the primary dose before bedtime in the evening. This timing is described as supporting the coordination of the product's effect with the body’s natural cycle.


Q: What makes Emuliquen simple 'simple' compared to other formulas?

The product information states that the 'simple' formulation contains Liquid Paraffin as the sole active ingredient. This single-component composition is the defined difference that sets it apart from other laxative products in the same brand family that may contain additional active substances.


Q: How is the safety of Emuliquen simple classified by regulatory bodies?

The medicine is classified by regulatory authorities as a laxative intended for the symptomatic relief of occasional constipation. Its safety profile is defined around the critical risk of aspiration (inhalation) and the systemic consequences of chronic use, such as nutrient interference.


Q: Does Emuliquen simple contain sugar or artificial sweeteners?

The official list of excipients (inactive ingredients) for some formulations includes Glycerol (E-422). Official guidance directs that the complete list of ingredients on the product label be reviewed for specific dietary requirements related to sugar or artificial sweeteners.


Q: Is it necessary to drink extra water when taking Emuliquen simple?

Official regulatory advice specifies the need to ingest at least 6 to 8 glasses of liquid per day during treatment. This practice is indicated to help produce soft stools and to protect against potential dehydration.


Q: Does the efficacy of Emuliquen simple decrease over time with repeated use?

Official documents state that prolonged use is not recommended because tolerance to the laxative effect may occur. Tolerance is described as a diminishing response to the medicine when taken repeatedly over time.


Q: Are there specific symptoms that mean someone should stop using Emuliquen simple?

Regulatory information provides conditions under which a consultation or review is indicated, such as if symptoms worsen or do not improve after 6 days of treatment. Similarly, guidance is indicated if no bowel movement occurs after 72 hours following maximum administration.


Q: Are allergic reactions to Emuliquen simple common or rare?

According to official safety information, allergic reactions are classified as a very rare side effect. These reactions are described as including symptoms such as a skin rash, swelling of the skin or face, or difficulty breathing.


Q: What are the general expectations for relief when using Emuliquen simple?

The administration instructions are structured to support defecation by the following morning after a night-time dose. The full laxative action is generally described in official documentation as being achieved from the third day after starting treatment.


Q: Is it possible for Emuliquen simple to interact with supplements like iron or calcium?

Regulatory documents indicate the product may interfere with the absorption of minerals such as calcium and phosphorus. This potential interference is related to the product’s physical mechanism of action, which can affect the uptake of orally administered substances.


Q: Is Emuliquen simple safe to use during pregnancy, according to official information?

Official information states that use during pregnancy is not recommended unless the expected benefit is determined to be greater than the potential risks. Furthermore, use during lactation is required by regulatory documents to be medically evaluated prior to use.


Q: Are there any known interactions with common herbal remedies?

Official warnings state that prolonged use may cause a reduction in potassium levels (hypokalaemia). This reduction can increase the risk of interaction with certain other substances, including those derived from plants (e.g., liquorice root), that also cause low potassium.

How should Emuliquen simple be stored and disposed of?

How to Store and Dispose of Emuliquen simple?

The storage and disposal of Emuliquen simple (Liquid Paraffin Oral Emulsion) must adhere strictly to official regulatory guidelines to maintain product quality and public safety.

Official Storage Requirements

Condition Requirement
Temperature Do not store above 25°C.
Protection Protect from light and keep from freezing.
Child Safety Keep out of the sight and reach of children.
Stability Do not use after the expiration date marked on the packaging.

Disposal Instructions

Unused or expired medicine and its packaging must not be discarded through household trash or wastewater systems. Instead, the product must be returned to a designated pharmacy collection point for proper pharmaceutical waste disposal, following local governmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Emuliquen simple found in:

A-Z Index: